<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33462068</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1757-790X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>18</Day></PubDate></JournalIssue><Title>BMJ case reports</Title><ISOAbbreviation>BMJ Case Rep</ISOAbbreviation></Journal><ArticleTitle>Late onset of Guillain-Barr&#xe9; syndrome following SARS-CoV-2 infection: part of 'long COVID-19 syndrome'?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e240178</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bcr-2020-240178</ELocationID><Abstract><AbstractText>We describe a case of delayed onset, acute demyelinating neuropathy secondary to novel SARS-CoV-2 infection. A previously healthy 46-year-old man presented with bilateral leg pain and loss of sensation in his feet 53 days after having COVID-19 pneumonitis. He developed painful sensory symptoms followed by a rapidly progressive lower motor neuron weakness involving all limbs, face and respiratory muscles, needing ventilatory support. In keeping with a diagnosis of Guillain-Barr&#xe9; syndrome, cerebrospinal fluid examination showed albuminocytologic dissociation and nerve conduction studies supported the diagnosis of an acute inflammatory demyelinating polyradiculoneuropathy. The delayed neurological dysfunction seen in our patient following SARS-CoV-2 infection may indicate a novel mechanism of disease that is part of the emerging 'long COVID-19 syndrome'.</AbstractText><CopyrightInformation>&#xa9; BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raahimi</LastName><ForeName>Mina M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Critical Care, Portsmouth Hospitals University NHS Trust, Portsmouth, UK mina.raahimi@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kane</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Acute Medical Unit, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Christopher Eg</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Neurophysiology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alareed</LastName><ForeName>Ahmad W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Neurophysiology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Case Rep</MedlineTA><NlmUniqueID>101526291</NlmUniqueID><ISSNLinking>1757-790X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004568" MajorTopicYN="N">Electrodiagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020275" MajorTopicYN="N">Guillain-Barre Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000067562" MajorTopicYN="N">Late Onset Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018908" MajorTopicYN="N">Muscle Weakness</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009431" MajorTopicYN="N">Neural Conduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009437" MajorTopicYN="N">Neuralgia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063087" MajorTopicYN="N">Noninvasive Ventilation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010292" MajorTopicYN="N">Paresthesia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">immunology</Keyword><Keyword MajorTopicYN="N">infectious diseases</Keyword><Keyword MajorTopicYN="N">neurology</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>19</Day><Hour>5</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33462068</ArticleId><ArticleId IdType="pmc">PMC7813388</ArticleId><ArticleId IdType="doi">10.1136/bcr-2020-240178</ArticleId><ArticleId IdType="pii">14/1/e240178</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pezzini A, Padovani A. Lifting the mask on neurological manifestations of COVID-19. Nat Rev Neurol 2020;16:636&#x2013;44. 10.1038/s41582-020-0398-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-0398-3</ArticleId><ArticleId IdType="pmc">PMC7444680</ArticleId><ArticleId IdType="pubmed">32839585</ArticleId></ArticleIdList></Reference><Reference><Citation>Othenin-Girard A, Regamey J, Lamoth F, et al. . Multisystem inflammatory syndrome with refractory cardiogenic shock due to acute myocarditis and mononeuritis multiplex after SARS-CoV-2 infection in an adult. Swiss Med Wkly 2020;150:w20387. 10.4414/smw.2020.20387</Citation><ArticleIdList><ArticleId IdType="doi">10.4414/smw.2020.20387</ArticleId><ArticleId IdType="pubmed">33181855</ArticleId></ArticleIdList></Reference><Reference><Citation>Needham E, Newcombe V, Michell A. Mononeuritis multiplex: an unexpectedly common feature of severe COVID-19. medRxiv 2020. 10.1101/2020.07.19.20149898</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.19.20149898</ArticleId><ArticleId IdType="pmc">PMC7690651</ArticleId><ArticleId IdType="pubmed">33244712</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E, Janvier P, Kherabi Y, et al. . Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect 2020;81:e4&#x2013;6. 10.1016/j.jinf.2020.08.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.029</ArticleId><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F, et al. . Persistent symptoms in patients after acute COVID-19. JAMA 2020;324:603&#x2013;5. 10.1001/jama.2020.12603</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, et al. . Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep 2020;69:993&#x2013;8. 10.15585/mmwr.mm6930e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6930e1</ArticleId><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn AF. Guillain-Barr&#xe9; syndrome. Lancet 1998;352:635&#x2013;41. 10.1016/S0140-6736(97)12308-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(97)12308-X</ArticleId><ArticleId IdType="pubmed">9746040</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropper AH. The Guillain-Barr&#xe9; syndrome. N Engl J Med 1992;326:1130&#x2013;6. 10.1056/NEJM199204233261706</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199204233261706</ArticleId><ArticleId IdType="pubmed">1552914</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P, Landary M. 
Recovery trial, 2020.  Available: https://www.recoverytrial.net/</Citation></Reference><Reference><Citation>Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barr&#xe9; syndrome. Ann Neurol 1990;27 Suppl:S21&#x2013;4. 10.1002/ana.410270707</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410270707</ArticleId><ArticleId IdType="pubmed">2194422</ArticleId></ArticleIdList></Reference><Reference><Citation>Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barr&#xe9; syndrome. Lancet 2016;388:717&#x2013;27. 10.1016/S0140-6736(16)00339-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)00339-1</ArticleId><ArticleId IdType="pubmed">26948435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan I, Saif-Ur-Rahman KM, Hayat S, et al. . Guillain-Barr&#xe9; syndrome associated with SARS-CoV-2 infection: a systematic review and individual participant data meta-analysis. J Peripher Nerv Syst 2020;25:335&#x2013;43. 10.1111/jns.12419</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jns.12419</ArticleId><ArticleId IdType="pubmed">33112450</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes RAC, Swan AV, Rapha&#xeb;l J-C, et al. . Immunotherapy for Guillain-Barr&#xe9; syndrome: a systematic review. Brain 2007;130): :2245&#x2013;57. 10.1093/brain/awm004</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm004</ArticleId><ArticleId IdType="pubmed">17337484</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg B, Walgaard C, Drenthen J, et al. . Guillain-Barr&#xe9; syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014;10:469&#x2013;82. 10.1038/nrneurol.2014.121</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.121</ArticleId><ArticleId IdType="pubmed">25023340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JE, Heo JH, Kim HO, et al. . Neurological complications during treatment of middle East respiratory syndrome. J Clin Neurol 2017;13:227&#x2013;33. 10.3988/jcn.2017.13.3.227</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2017.13.3.227</ArticleId><ArticleId IdType="pmc">PMC5532318</ArticleId><ArticleId IdType="pubmed">28748673</ArticleId></ArticleIdList></Reference><Reference><Citation>Uncini A, Vallat J-M, Jacobs BC. Guillain-Barr&#xe9; syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic. J Neurol Neurosurg Psychiatry 2020;91:1105&#x2013;10. 10.1136/jnnp-2020-324491</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-324491</ArticleId><ArticleId IdType="pubmed">32855289</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Rumeileh S, Abdelhak A, Foschi M. Guillain-Barr&#xe9; syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol 2020:1&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445716</ArticleId><ArticleId IdType="pubmed">32840686</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, McAuley DF, Brown M, et al. . COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033&#x2013;4. 10.1016/S0140-6736(20)30628-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30628-0</ArticleId><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Kragholm K, Andersen MP, Gerds TA, et al. . Association between male sex and outcomes of Coronavirus Disease 2019 (Covid-19) - a Danish nationwide, register-based study. Clin Infect Dis 2020. 10.1093/cid/ciaa924. [Epub ahead of print: 08 Jul 2020].</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa924</ArticleId><ArticleId IdType="pmc">PMC7454435</ArticleId><ArticleId IdType="pubmed">32634827</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrillo-Larco RM, Altez-Fernandez C, Ravaglia S, et al. . COVID-19 and Guillain-Barre syndrome: a systematic review of case reports. Wellcome Open Res 2020;5:107. 10.12688/wellcomeopenres.15987.2</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.15987.2</ArticleId><ArticleId IdType="pmc">PMC7509591</ArticleId><ArticleId IdType="pubmed">32995555</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Shen D, Zhou H, et al. . Guillain-Barr&#xe9; syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol 2020;19:383&#x2013;4. 10.1016/S1474-4422(20)30109-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30109-5</ArticleId><ArticleId IdType="pmc">PMC7176927</ArticleId><ArticleId IdType="pubmed">32246917</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson RW, Brown RL, Benjamin L, et al. . The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain 2020;143:3104&#x2013;20. 10.1093/brain/awaa240</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa240</ArticleId><ArticleId IdType="pmc">PMC7454352</ArticleId><ArticleId IdType="pubmed">32637987</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>